Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Accrued Liabilities

v3.24.3
Note 8 - Accrued Liabilities
9 Months Ended
Sep. 30, 2024
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

8.         Accrued Liabilities

 

Accrued liabilities consisted of the following (in thousands):

 

   

September 30, 2024

   

December 31, 2023

 

Clinical trial costs

  $ 1,297     $ 258  

Research and development services

    896       632  

Compensation

    730       766  

Professional services fees

    91       98  

Other

    10       23  

Total accrued liabilities

  $ 3,024     $ 1,777